-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
Actively -X- _ O
recruit -X- _ O
and -X- _ O
intensively -X- _ O
follow -X- _ O
pregnant -X- _ B-Patient
women -X- _ I-Patient
receiving -X- _ O
a -X- _ O
dose -X- _ O
of -X- _ O
acellular -X- _ B-Intervention
pertussis -X- _ I-Intervention
vaccine -X- _ I-Intervention
for -X- _ I-Intervention
4 -X- _ I-Intervention
weeks -X- _ I-Intervention
after -X- _ O
vaccination. -X- _ O
DESIGN -X- _ O
AND -X- _ O
SETTINGS -X- _ O
: -X- _ O
A -X- _ O
prospective -X- _ O
observational -X- _ O
study -X- _ O
conducted -X- _ O
in -X- _ O
2 -X- _ O
New -X- _ O
Zealand -X- _ O
regions. -X- _ O
PARTICIPANTS -X- _ O
: -X- _ O
Women -X- _ B-Patient
in -X- _ I-Patient
their -X- _ I-Patient
28thâ€“ -X- _ I-Patient
38th -X- _ I-Patient
week -X- _ I-Patient
of -X- _ I-Patient
pregnancy -X- _ I-Patient
, -X- _ O
recruited -X- _ O
from -X- _ O
primary -X- _ O
care -X- _ O
and -X- _ O
antenatal -X- _ O
clinics -X- _ O
at -X- _ O
the -X- _ O
time -X- _ O
of -X- _ O
Tdap -X- _ B-Intervention
administration. -X- _ I-Intervention
Telephone -X- _ O
interviews -X- _ O
were -X- _ O
conducted -X- _ O
at -X- _ O
48 -X- _ O
h -X- _ O
and -X- _ O
4 -X- _ O
weeks -X- _ O
postvaccination. -X- _ O
MAIN -X- _ O
OUTCOMES -X- _ O
MEASURES -X- _ O
: -X- _ O
Outcomes -X- _ O
were -X- _ O
injection -X- _ O
site -X- _ O
reactions -X- _ O
, -X- _ O
systemic -X- _ O
symptoms -X- _ O
and -X- _ O
serious -X- _ O
adverse -X- _ O
events -X- _ O
( -X- _ O
SAEs -X- _ O
) -X- _ O
. -X- _ O
Where -X- _ O
available -X- _ O
, -X- _ O
data -X- _ O
have -X- _ O
been -X- _ O
classified -X- _ O
and -X- _ O
reported -X- _ O
according -X- _ O
to -X- _ O
Brighton -X- _ O
Collaboration -X- _ O
definitions. -X- _ O
RESULTS -X- _ O
: -X- _ O
793 -X- _ B-Outcome
women -X- _ I-Outcome
participated -X- _ I-Outcome
with -X- _ I-Outcome
27.9 -X- _ I-Outcome
% -X- _ I-Outcome
receiving -X- _ I-Outcome
trivalent -X- _ I-Outcome
inactivated -X- _ I-Outcome
influenza -X- _ I-Outcome
vaccine -X- _ I-Outcome
concomitantly. -X- _ I-Outcome
79 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
participants -X- _ I-Outcome
reported -X- _ I-Outcome
mild -X- _ I-Outcome
or -X- _ I-Outcome
moderate -X- _ I-Outcome
pain -X- _ I-Outcome
and -X- _ I-Outcome
2.6 -X- _ I-Outcome
% -X- _ I-Outcome
severe -X- _ I-Outcome
pain. -X- _ I-Outcome
Any -X- _ I-Outcome
swelling -X- _ I-Outcome
was -X- _ I-Outcome
reported -X- _ I-Outcome
by -X- _ I-Outcome
7.6 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
induration -X- _ I-Outcome
by -X- _ I-Outcome
12.0 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
collected -X- _ I-Outcome
from -X- _ I-Outcome
1 -X- _ I-Outcome
site -X- _ I-Outcome
only -X- _ I-Outcome
, -X- _ I-Outcome
n=326 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
erythema -X- _ I-Outcome
by -X- _ I-Outcome
5.8 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
participants. -X- _ I-Outcome
Fever -X- _ I-Outcome
was -X- _ I-Outcome
reported -X- _ I-Outcome
by -X- _ I-Outcome
17 -X- _ I-Outcome
( -X- _ I-Outcome
2.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
participants -X- _ I-Outcome
, -X- _ I-Outcome
14 -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
occurred -X- _ I-Outcome
within -X- _ I-Outcome
24 -X- _ I-Outcome
h. -X- _ I-Outcome
Headache -X- _ I-Outcome
, -X- _ I-Outcome
dizziness -X- _ I-Outcome
, -X- _ I-Outcome
nausea -X- _ I-Outcome
, -X- _ I-Outcome
myalgia -X- _ I-Outcome
or -X- _ I-Outcome
arthralgia -X- _ I-Outcome
was -X- _ I-Outcome
reported -X- _ I-Outcome
by -X- _ I-Outcome
< -X- _ I-Outcome
4 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
participants -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
fatigue -X- _ I-Outcome
by -X- _ I-Outcome
8.4 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
During -X- _ I-Outcome
the -X- _ I-Outcome
study -X- _ I-Outcome
period -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
were -X- _ I-Outcome
115 -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
in -X- _ I-Outcome
113 -X- _ I-Outcome
participants -X- _ I-Outcome
, -X- _ I-Outcome
most -X- _ I-Outcome
of -X- _ I-Outcome
which -X- _ I-Outcome
were -X- _ I-Outcome
minor. -X- _ I-Outcome
At -X- _ I-Outcome
the -X- _ I-Outcome
end -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
reporting -X- _ I-Outcome
period -X- _ I-Outcome
, -X- _ I-Outcome
31 -X- _ I-Outcome
events -X- _ I-Outcome
were -X- _ I-Outcome
classified -X- _ I-Outcome
as -X- _ I-Outcome
serious -X- _ I-Outcome
( -X- _ I-Outcome
eg -X- _ I-Outcome
, -X- _ I-Outcome
obstetric -X- _ I-Outcome
bleeding -X- _ I-Outcome
, -X- _ I-Outcome
hypertension -X- _ I-Outcome
, -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
tachycardia -X- _ I-Outcome
, -X- _ I-Outcome
preterm -X- _ I-Outcome
labour -X- _ I-Outcome
, -X- _ I-Outcome
exacerbation -X- _ I-Outcome
of -X- _ I-Outcome
pre-existing -X- _ I-Outcome
condition -X- _ I-Outcome
and -X- _ I-Outcome
pre-eclampsia -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
All -X- _ I-Outcome
had -X- _ I-Outcome
variable -X- _ I-Outcome
onset -X- _ I-Outcome
time -X- _ I-Outcome
from -X- _ I-Outcome
vaccination. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
two -X- _ I-Outcome
perinatal -X- _ I-Outcome
deaths. -X- _ I-Outcome
Clinician -X- _ I-Outcome
assessment -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
SAEs -X- _ I-Outcome
found -X- _ I-Outcome
none -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
vaccine -X- _ I-Outcome
related. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Vaccination -X- _ B-Outcome
with -X- _ I-Outcome
Tdap -X- _ I-Outcome
in -X- _ I-Outcome
pregnant -X- _ I-Outcome
women -X- _ I-Outcome
was -X- _ I-Outcome
well -X- _ I-Outcome
tolerated -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
SAE -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
caused -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
vaccine. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
NUMBER -X- _ O
: -X- _ O
ACTRN12613001045707 -X- _ O
. -X- _ O

